Vertex Pharmaceuticals
-
Vertex Pays CRISPR Therapeutics $100M to Bring Gene-Editing to Type 1 Diabetes
Vertex Pharmaceuticals aims to use CRISPR Therapeutics’ gene-editing technology to develop type 1 diabetes cell therapies that don’t prompt the immune system to reject them. This approach could compete with a Sana Biotechnology program expected to reach its first test in humans this year.
-
Vertex builds up pipeline of type 1 diabetes cell therapies with $320M buyout
Vertex Pharmaceuticals already has a cell therapy candidate for type 1 diabetes but the company says acquiring rival ViaCyte will provide it with complementary assets and technologies. The two companies already share a partner in common: both have therapeutic candidates that use the gene-editing capabilities of CRISPR Therapeutics.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Vertex Pharma inks another R&D alliance to expand its gene-editing ambitions
Vertex Pharmaceuticals is collaborating with Obsidian Therapeutics to develop up to five new gene editing therapies. Obsidian’s technology precisely controls protein expression, a capability the partners plan to apply to several undisclosed serious diseases.
-
Vertex to pay CRISPR Therapeutics $900M for bigger share of gene-editing alliance
Vertex Pharmaceuticals is amending its collaboration with CRISPR Therapeutics, paying $900 million now for chance to grab a bigger share of a gene-editing therapy’s profits later—if the treatment is approved. Clinical trials evaluating the CRISPR-based therapy are underway in sickle cell disease and beta thalassemia.
-
Presentations at EHA highlight gene therapy approaches to beta-thalassemia, sickle cell disease
Phase III data on bluebird bio’s Zynteglo, as well as Vertex and CRISPR Therapeutics’ CTX001, showed patients achieving transfusion independence via two gene therapy approaches.
-
Drugmakers’ financial fortunes during Covid-19 may hinge on their product mix
Analyst reports over the past few weeks have looked into what effects the Covid-19 pandemic could have on drugmakers’ sales, examining multiple factors. But virtual launches and telemedicine could mitigate some market challenges.
-
ViralClear appoints former Celgene exec as chair, dusts off long-shelved hepatitis C drug for Covid-19 trial
The company, part of BioSig Technologies, aims to run a Phase II study of the drug, merimepodib, which had previously failed in a Phase IIb HCV study run by Vertex Pharmaceuticals. The company hopes the drug’s mechanism could prove effective against SARS-CoV-2.
-
As Covid-19 hinders clinical trial operations, research staff are finding themselves out of work
A recruiter in the industry said trial-monitoring staff report having their hours cut, while CRAs are grounded, and others have reported being laid off on social media. Several drugmakers have wound down clinical trial operations as the pandemic has overwhelmed a growing number of hospitals.
-
Vertex eyes virtual trial visits as Covid-19 pandemic spreads, but no product supply snags anticipated
The biotech company said it is well-stocked to supply its approved drugs for cystic fibrosis to patients. Meanwhile, it plans to implement virtual visits and ship drugs to participants in its ongoing trials, while pausing enrollment and delaying initiation in some.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
FDA approves Vertex’s triple combo therapy for cystic fibrosis 5 months ahead of schedule
Shares of the company rose 9 percent on the news that the FDA had approved Trikafta. The drug will be an option for patients using the company’s other approved CF drugs.
-
Vertex buys developer of preclinical cell therapy for Type 1 diabetes for $950M
The Boston-based company said it would acquire Semma Therapeutics, which is developing a stem cell-derived therapy and device for the disease. Preclinical data were announced in July, and clinical trials are planned for 2020.
-
Vertex, CRISPR Therapeutics infuse first patient in CRISPR/Cas9-based gene therapy study
The Phase I/II trial is in beta-thalassemia, a rare blood disorder. Another Phase I/II study of the same drug, in sickle cell disease, is expected to infuse its first patient in mid-2019.
-
Editas Medicine CEO steps down as company moves into product development stage
Shares of gene-editing companies were down Tuesday morning following the news, but analysts sought to reassure investors about Editas.
-
FDA green-lights CRISPR Therapeutics, Vertex Pharmaceuticals’ gene-editing study
The agency also accepted the two companies’ IND to begin the Phase I/II study of CTX001 in patients with sickle cell disease, sending CRISPR shares up more than 11 percent Thursday morning.
-
Genomics raises $32.5M to develop genetic database technology for drug development
Boston-based drugmaker Vertex Pharmaceuticals leads the round and also enters partnership with UK firm to aid its own drug development efforts.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
